Incyclix Bio, a Reserch Thriangle Park, NC-based cell cycle control company, raised $30M in Series B funding.
The round was led by Boxer Capital with participation from RA Capital Management and Eshelman Ventures.
Sid Subramony, Ph.D., Vice President of Boxer Capital, will join Incyclix Bio’s board of directors. Nathaniel Brooks Horwitz, Principal of RA Capital Management, will join Incyclix Bio as a board observer.
The company intends to use the funds for the clinical development of its lead compound, INX-315, a novel, potent and selective CDK2 inhibitor with compelling preclinical efficacy and safety data. Incyclix Bio expects to initiate a proof-of-concept Phase 1/2 study of INX-315 in CDK4/6-resistant and Cyclin E-overexpressed cancers, including breast and ovarian cancer.
Led by Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder, Incyclix Bio is a cell cycle control company advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers.
FinSMEs
04/04/2022